Lassiter Wright III 4

What Happened Lassiter Wright III, a director of Quest Diagnostics (DGX), acquired 7 shares on January 28, 2026 at $183.51 per share, for a total value of about $1,285. The Form 4 was filed with the SEC on February 20, 2026 (Period of Report: 2026-01-28). This was a purchase (acquisition) rather than a sale, but the amount is small and stems from dividend reinvestment rather than an open-market buy.

Key Details

• Transaction date: 2026-01-28; Price: $183.51 per share; Shares acquired: 7; Total value ≈ $1,285.
• Filing date: 2026-02-20 (Form 4 accession 0001022079-26-000011). The transaction line is marked "(L)"; however, footnote F1 states these shares were acquired through a broker-administered dividend reinvestment plan and the reporting person elected to report the transaction on this Form 4.
• Footnote F2: the amount includes shares acquired via dividend reinvestment since the reporting person's last Form 4.
• Shares owned after the transaction: not specified in the provided summary.

Context

• These shares were issued via a dividend reinvestment plan (DRIP), a routine corporate action that typically reflects reinvested dividends rather than a deliberate market purchase — therefore it conveys limited insight into the director’s market sentiment.
• The purchase amount is small (~$1.3k) and is common in DRIP activity; retail investors should treat this as routine insider activity rather than a strong bullish signal.